Product image of Meriofert (Luteinising Hormone (Human), Follicle-Stimulating Hormone) supplied by GNH India

Meriofert

Active Ingredient:
Luteinising Hormone (Human), Follicle-Stimulating Hormone
Origin:
EU

Meriofert (Luteinising Hormone (Human), Follicle-Stimulating Hormone)

Luteinising hormone (human), Follicle‑stimulating hormone, the active ingredient in Meriofert, is a gonadotropin presented as an injectable preparation for intramuscular or subcutaneous use. It is used to treat infertility related to anovulation, hypogonadotropic hypogonadism, and to support assisted reproductive technologies such as in‑vitro fertilisation. The product contains a combination of human LH and FSH that mimics natural pituitary secretion.

GNH India supplies Meriofert as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Ibsa Farmaceutici Italia

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Meriofert, a gonadotropin preparation, is indicated for conditions involving impaired ovarian function and hormonal deficiency.

  • Infertility due to anovulation: stimulates follicular development and induces ovulation.
  • Hypogonadotropic hypogonadism: replaces deficient LH and FSH to restore normal gonadal function.
  • Assisted reproductive technology (e.g., in vitro fertilisation): supports controlled ovarian stimulation for oocyte retrieval.

How It Works

  • Meriofert provides recombinant human luteinising hormone (LH) and follicle‑stimulating hormone (FSH) that bind to their respective gonadotropin receptors on ovarian granulosa and theca cells. Activation of the FSH receptor promotes follicular growth and estrogen synthesis, while LH receptor activation triggers final maturation, ovulation and luteinisation. The combined activity restores the natural endocrine cascade required for oocyte development.

Side Effects

Meriofert may be associated with a range of adverse reactions following injection.

Common Side Effects

  • Injection site pain: mild to moderate discomfort at the injection site.
  • Headache: transient headache of varying intensity.
  • Nausea: occasional nausea without vomiting.
  • Abdominal discomfort: mild abdominal cramps or bloating.
  • Ovarian hyperstimulation syndrome (mild): mild symptoms such as abdominal distension.

Serious or Rare Side Effects

  • Ovarian hyperstimulation syndrome (severe): marked ovarian enlargement, ascites, thromboembolism.
  • Thromboembolic events: deep vein thrombosis or pulmonary embolism.
  • Allergic reaction: rash, urticaria, or anaphylaxis.
  • Ectopic pregnancy: occurrence of pregnancy outside the uterus.
  • Multiple pregnancy: higher‑order gestations (triplets or more).

Precautions & Warnings

Before using Meriofert, clinicians should consider several precautionary measures to minimise risks.

  • Patient assessment: evaluate ovarian reserve and baseline hormone levels.
  • Monitoring: perform regular ultrasound and estradiol monitoring during treatment.
  • OHSS risk: assess risk factors such as polycystic ovary syndrome and adjust dose accordingly.
  • Contraindications: avoid use in known hypersensitivity to gonadotropins or active ingredients.
  • Pregnancy status: discontinue if pregnancy is confirmed before intended ovulation trigger.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Meriofert can interact with other medications that affect hormonal balance or coagulation.

Major Interactions (Avoid)

  • GnRH agonists/antagonists: may alter the intended gonadotropin response.
  • Anticoagulants: increased risk of bleeding with severe ovarian hyperstimulation.
  • Aromatase inhibitors: may interfere with estrogen synthesis during stimulation.

Moderate Interactions (Monitor Closely)

  • Corticosteroids: may affect ovarian response, requiring dose adjustment.
  • Thyroid hormones: abnormal thyroid status can modify gonadotropin efficacy.
  • Insulin or oral hypoglycemics: hyperstimulation may affect glucose metabolism.

Frequently Asked Questions

Meriofert is a gonadotropin preparation indicated for infertility caused by anovulation, for patients with hypogonadotropic hypogonadism, and as part of assisted reproductive technology protocols such as in‑vitro fertilisation to stimulate ovarian follicle development and ovulation.

The LH component binds to LH receptors on theca cells, promoting androgen production that is converted to estrogen, while the FSH component activates FSH receptors on granulosa cells, stimulating follicular growth and estrogen synthesis. Together they mimic the natural pituitary signal that leads to final oocyte maturation and ovulation.

The dose of Meriofert is individualized. A qualified prescriber determines the amount, frequency and duration of treatment based on the patient’s hormonal profile, ovarian response and the specific assisted‑reproduction protocol being used.

Meriofert is intended for use before conception to achieve pregnancy. It is not recommended for use during an established pregnancy or while breastfeeding, and treatment should be discontinued once pregnancy is confirmed unless a specialist advises otherwise.

To order Meriofert, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if required) and the necessary import documentation.

Meriofert combines both LH and FSH in a single preparation, whereas some alternatives provide only recombinant FSH (e.g., Gonal‑F) or separate LH preparations. The combined formulation can simplify dosing schedules and may better mimic natural pituitary output, but choice depends on individual patient response and clinician preference.

Meriofert must be stored at 2‑8 °C (refrigerated), protected from light, and should never be frozen or shaken. Keep the product in its original packaging until use and discard any vial that has been left at room temperature for longer than the time specified in the label.

Meriofert is administered by intramuscular or subcutaneous injection. The vial is reconstituted with the appropriate diluent according to the label, and the dose is injected using a sterile needle and syringe under aseptic technique, following the prescriber’s instructions.

The most serious risks include severe ovarian hyperstimulation syndrome (OHSS) which can lead to ovarian rupture, thromboembolic events, allergic reactions such as anaphylaxis, and the possibility of multiple or ectopic pregnancies. Patients should be monitored closely for these complications.

Meriofert should not be used in individuals with known hypersensitivity to human LH or FSH, in patients with uncontrolled ovarian cysts, active ovarian or breast cancer, severe uncontrolled endocrine disorders, or in women who are already pregnant.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Luteinising Hormone (Human), Follicle-Stimulating Hormone

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT